How can patients get started with KISQALI + AI?
Standard assessments are required before starting treatment with KISQALI® (ribociclib), in combination with an aromatase inhibitor (AI), for patients with stage II/III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (eBC) at high risk of recurrence. Ongoing guidance and resources are available for dosing, dose adjustments, and support to help you and your patients approach treatment with confidence.1
STARTING KISQALI
A few standard assessments help to ensure your patients start right away
- Complete blood count (CBC)1
- Electrocardiogram (ECG)1,*
- Electrolytes1,†
- Liver function tests (LFTs)1,‡
Straightforward ECG testing
- The 2 required ECGs are performed at baseline and on Day 14 of Cycle 1—within the first 2 weeks of treatment1
- If you are unable to perform ECGs in office, speak with your Novartis Oncology Specialist about a simple solution for fast, easy, and accurate ECG testing
AI, aromatase inhibitor; QTcF, QT interval corrected by Fridericia’s formula.
*KISQALI should only be initiated in patients with QTcF <450 ms.1
†Monitor serum electrolytes prior to the initiation of treatment, at the beginning of each of the first 6 cycles, and as clinically indicated. Correct any electrolyte abnormalities before initiating treatment.1
‡Monitor LFTs prior to the initiation of treatment, every 2 weeks for the first 2 cycles, at the beginning of each of the subsequent 4 cycles, and as clinically indicated. For LFTs, if grade ≥2 abnormalities are noted, more frequent monitoring is recommended.1
Additional monitoring may be required as clinically indicated.
Incidence of QT prolongation observed with KISQALI was low
Among cases of QT prolongation1:
0.3% had a >500 ms postbaseline QTcF value
2% had a >60 ms increase from baseline in QTcF interval
There were no reported cases of torsades de pointes
DOSING & ADJUSTMENTS
What is the KISQALI starting dose for patients with stage II/III HR+/HER2- eBC at high risk of recurrence?
400 mg is the starting dose for KISQALI in eBC—chosen to help reduce both the risk of recurrence and dose-dependent ARs
KISQALI single-strength tablets make dose reduction simple and convenient—with no need for new mid-cycle prescriptions or additional costs1
KISQALI is given as 400 mg (2 x 200-mg tablets) orally, once daily (3 weeks on, 1 week off) for 36 months with an AI1
Review the full Prescribing Information for recommended dosing of selected AI
An LHRH agonist should be used concomitantly with AI in men and premenopausal women
Patients should continue treatment for 3 years or until disease recurrence or unacceptable toxicity
KISQALI can be taken with or without food
Patients may store at room temperature at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F)
Store in the original blister package in order to protect from moisture
Starting dose modification for severe renal impairment
The recommended starting dose is 200 mg once daily for patients with severe renal impairment
Dose adjustments for adverse reactions should be made by reducing the number of tablets taken. Dose modification of KISQALI is recommended based on individual safety and tolerability. If dose reduction below 200 mg/day is required, discontinue treatment.1
AR, adverse reaction; eBC, early breast cancer; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; LHRH, luteinizing hormone-releasing hormone.
NOVARTIS PATIENT SUPPORT™
What is Novartis Patient Support?
Novartis Patient Support is a dedicated team for your patients—a comprehensive program, designed to help your eligible patients start, stay, and save on KISQALI.
We support your patient’s journey with:
Dedicated assistance with access and reimbursement
Personalized support for your patients on therapy
Single points of contact for you and your patients
Get your patients started by downloading the Start Form.
More than 9 out of 10 patients have preferred formulary coverage for KISQALI |
>98% unrestricted coverage in Commercial and Medicare, based on MMIT data, as of June 2026.3
Novartis does not guarantee payment or coverage for any product or service. Actual coverage and reimbursement decisions are made by individual payers following receipt of claims. Coverage is subject to change by the relevant payer.